Developing a remotely delivered intensive outpatient program adapted for hospitalized patients with opioid use disorder: A qualitative study.

Hospital Injection-related infection Intensive outpatient program Intravenous drug use Opioid use disorder Peer recovery coach

Journal

Addictive behaviors reports
ISSN: 2352-8532
Titre abrégé: Addict Behav Rep
Pays: Netherlands
ID NLM: 101656077

Informations de publication

Date de publication:
Jun 2024
Historique:
received: 29 01 2024
revised: 01 04 2024
accepted: 17 04 2024
medline: 29 4 2024
pubmed: 29 4 2024
entrez: 29 4 2024
Statut: epublish

Résumé

Individuals with opioid use disorder (OUD) who inject drugs have an elevated risk of experiencing serious injection-related infections. While such infections can be treated, treatment for the underlying OUD is often limited. One potential strategy for more intensive addiction treatment is to offer a remotely delivered intensive outpatient program (IOP), adapted from an existing remote IOP ("Smart IOP"). We aimed to conduct a qualitative study to gather feedback on Smart IOP and identify adaptations needed for hospitalized patients. Individuals with OUD and a history of serious injection-related infections completed a semi-structured interview and were shown samples of the videos and program content. The interviews were transcribed verbatim and coded to conduct a thematic analysis. Seventeen individuals participated. The mean age was 40.8 years and 70.6 % were men. Participants reported that IOP during the hospitalization would have been helpful to their recovery. The themes that emerged were the importance of medications for OUD, having a relapse prevention plan, engaging with a recovery coach, and ensuring treatment linkage post-discharge. Other themes included the recognition of the severity of one's illness and the emotional experiences related to the hospitalization. Participants expressed the value of an IOP during hospitalization and provided insights into the support needed while hospitalized. The tailored IOP is now being developed and will undergo a pilot feasibility trial.

Identifiants

pubmed: 38680207
doi: 10.1016/j.abrep.2024.100546
pii: S2352-8532(24)00023-3
pmc: PMC11046241
doi:

Types de publication

Journal Article

Langues

eng

Pagination

100546

Informations de copyright

© 2024 The Authors. Published by Elsevier Ltd.

Déclaration de conflit d'intérêts

The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Dr. Weiss reports consultation with Alkermes. All other authors report no conflicts of interest. The authors alone are responsible for the content and writing of this paper.

Auteurs

Veronica Szpak (V)

Department of Psychiatry, Brigham and Women's Hospital, Boston, MA, United States.

Sara Prostko (S)

Department of Psychiatry, Brigham and Women's Hospital, Boston, MA, United States.

Roger D Weiss (RD)

Department of Psychiatry, Harvard Medical School, Boston, MA, United States.
Division of Alcohol, Drugs, and Addiction, McLean Hospital, Belmont, MA, United States.

Joji Suzuki (J)

Department of Psychiatry, Brigham and Women's Hospital, Boston, MA, United States.
Department of Psychiatry, Harvard Medical School, Boston, MA, United States.

Classifications MeSH